3524-16-1

Basic information

• Product Name: 1-ISOPROPYL-1H-PYRAZOL-5-AMINE
• Synonyms: 1-isopropyl-1H-pyrazol-5-amine(SALTDATA: FREE);1-isopropyl-1H-pyrazol-5-amine hydrochloride;(2-isopropylpyrazol-3-yl)amine;2H-Pyrazole, 3-amino-2-isopropyl-;2-isopropyl-3-pyrazolamine;2-isopropylpyrazol-3-amine;2-propan-2-ylpyrazol-3-amine
• CAS NO: 3524-16-1
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17
• Mol File: 3524-16-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 234.2°Cat760mmHg
• Flash Point: 95.4°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0.0536mmHg at 25°C
• Refractive Index: 1.566
• CAS DataBase Reference: 1-ISOPROPYL-1H-PYRAZOL-5-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ISOPROPYL-1H-PYRAZOL-5-AMINE(3524-16-1)
• EPA Substance Registry System: 1-ISOPROPYL-1H-PYRAZOL-5-AMINE(3524-16-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 3524-16-1(Hazardous Substances Data)

Usage

General Description

1-ISOPROPYL-1H-PYRAZOL-5-AMINE is a chemical compound with the molecular formula C6H12N2. It is a pyrazole derivative, which is a class of organic compounds containing a five-membered aromatic ring with two nitrogen atoms. 1-ISOPROPYL-1H-PYRAZOL-5-AMINE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential use in the development of new materials and as a building block for the synthesis of various organic compounds. Additionally, 1-ISOPROPYL-1H-PYRAZOL-5-AMINE has been found to exhibit biological activities, making it a subject of interest in the research and development of new drugs and therapeutic agents.

InChI:InChI=1/C6H11N3/c1-5(2)9-6(7)3-4-8-9/h3-5H,7H2,1-2H3

Upstream product

• 26262-07-7 5-amino-1-isopropyl-1H-pyrazole-4-carboxylic acid 
• 70629-60-6 isopropylhydrazine hydrochloride 
• 920-37-6 2-Chloroacrylonitrile 
• 30292-77-4 3-<(1-methylethylidene)hydrazino>propanenitrile 
• 1759-24-6 5-amino-1-isopropyl-1H-pyrazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1570369-82-2 1-isopropyl-5-methyl-4,6-diphenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 1570369-84-4 1-isopropyl-4-(4-methoxyphenyl)-5-methyl-6-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 877973-38-1 5-cyclopropyl-1-isopropyl-4-(4-methoxyphenyl)-6-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 877973-35-8 4-(4-chlorophenyl)-5-cyclopropyl-1-isopropyl-6-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 930732-43-7 5-cyclopropyl-6-(4-fluorophenyl)-1-isopropyl-4-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 1570369-94-6 5-cyclopropyl-6-(4-fluorophenyl)-1-isopropyl-4-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 1006463-43-9 N-(2-isopropyl-2H-pyrazol-3-yl)-N'-methylbenzamidine 
• 1006463-51-9 N'-cyclopropyl-N-(2-isopropyl-2H-pyrazol-3-yl)benzamidine 
• 1006463-55-3 4-fluoro-N-(2-isopropyl-2H-pyrazol-3-yl)-N'-methylbenzamidine 
• 1570369-90-2 6-(4-fluorophenyl)-1-isopropyl-5-methyl-4-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine 
• 1006482-06-9 N'-cyclopropyl-4-fluoro-N-(2-isopropyl-2H-pyrazol-3-yl)benzamidine 
• 1006482-12-7 N'-isopropyl-N-(2-isopropyl-2H-pyrazol-3-yl)benzamidine 
• 883544-72-7 6-methyl-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 

Relevant articles and documents

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.

USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD)

In some aspects, the instant disclosure relates to methods of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering to a subject in need thereof a EZH2 inhibitor, a Bcl6 inhibitor and/or BRD4 inhibitor. The present disclosure is based, at least in part, on the discovery that enhancer of zeste homolog 2 (EZH2) inhibitors, B-cell lymphoma 6 protein (Bcl6) inhibitors and/or bromodomain-containing protein 4 (BRD4) inhibitors can be used to treat chronic graft versus host disease (cGVHD).

Approach to the library of fused pyridine-4-carboxylic acids by combes-type reaction of acyl pyruvates and electron-rich amino heterocycles

A library of fused pyridine-4-carboxylic acids (including pyrazolo[3,4-b]pyridines, isoxazolo[5,4-b]pyridines, furo[2,3-b]pyridines, thieno[2,3-b]pyridines, and pyrido[2,3-d]pyrimidines) was generated by Combes-type reaction of acyl pyruvates and electron-rich amino heterocycles followed by hydrolysis of the ester. The library members were also demonstrated to undergo the standard combinatorial transformations including amide coupling and esterification, as well as less common heterocyclizations to 1,2,4-triazoles and 1,2,4-oxadiazoles.